Paper24736743
A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.
Knudson SE and 8 others. PLoS One, 2014. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis. Papers, record 24736743. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24736743
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antitubercular Agents | Major topic |
| Benzimidazoles | Major topic |
| Cell Division | Major topic |
| Mycobacterium tuberculosis | Major topic |
| Animals | |
| Bacterial Proteins | |
| Cytoskeletal Proteins | |
| Disease Models, Animal | |
| Dose-Response Relationship, Drug | |
| Drug Stability | |
| Humans | |
| Mice | |
| Microbial Sensitivity Tests | |
| Molecular Structure | |
| Protein Multimerization | |
| Rifamycins | |
| Treatment Outcome | |
| Tuberculosis |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U01 AI082164 | NIAID NIH HHS | United States | U01AI082164 | PubMed and NIH | NIH RePORTER |
| AIO78251 | PHS HHS | United States | PubMed | PubMed | |
| AI082164 | NIAID NIH HHS | United States | U01AI082164 | PubMed and NIH | NIH RePORTER |
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22535945 | Complete annotated genome sequence of Mycobacterium tuberculosis Erdman. | J Bacteriol | 2012 | https://conductscience.org/library/papers/22535945 | PubMed |
| 2 | 22024272 | Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors. | Bioorg Med Chem | 2011 | https://conductscience.org/library/papers/22024272 | PubMed |
| 3 | 20385864 | In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. | Antimicrob Agents Chemother | 2010 | https://conductscience.org/library/papers/20385864 | PubMed |
| 4 | 17664324 | Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. | Antimicrob Agents Chemother | 2007 | https://conductscience.org/library/papers/17664324 | PubMed |
| 5 | 17301295 | XDR tuberculosis--implications for global public health. | N Engl J Med | 2007 | https://conductscience.org/library/papers/17301295 | PubMed |
| 6 | 18479968 | Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery. | Tuberculosis (Edinb) | 2008 | https://conductscience.org/library/papers/18479968 | PubMed |
| 7 | 17346197 | FtsZ: a novel target for tuberculosis drug discovery. | Curr Top Med Chem | 2007 | https://conductscience.org/library/papers/17346197 | PubMed |
| 8 | 23623254 | Benzimidazole-based antibacterial agents against Francisella tularensis. | Bioorg Med Chem | 2013 | https://conductscience.org/library/papers/23623254 | PubMed |
| 9 | 23647650 | A novel quinoline derivative that inhibits mycobacterial FtsZ. | Tuberculosis (Edinb) | 2013 | https://conductscience.org/library/papers/23647650 | PubMed |
| 10 | 16420032 | Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. | J Med Chem | 2006 | https://conductscience.org/library/papers/16420032 | PubMed |
| 11 | 12368430 | Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. | Microbiology (Reading) | 2002 | https://conductscience.org/library/papers/12368430 | PubMed |
| 12 | 24266862 | SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents. | J Med Chem | 2013 | https://conductscience.org/library/papers/24266862 | PubMed |
| 13 | 16735741 | Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis. | Microbiology (Reading) | 2006 | https://conductscience.org/library/papers/16735741 | PubMed |
| 14 | 21339840 | Discovery of anti-TB agents that target the cell-division protein FtsZ. | Future Med Chem | 2010 | https://conductscience.org/library/papers/21339840 | PubMed |
| 15 | 11069675 | Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. | Mol Microbiol | 2000 | https://conductscience.org/library/papers/11069675 | PubMed |
| 16 | 9145860 | Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9145860 | PubMed |
| 17 | 12543692 | Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. | Antimicrob Agents Chemother | 2003 | https://conductscience.org/library/papers/12543692 | PubMed |
| 18 | 17868596 | First tuberculosis cases in Italy resistant to all tested drugs. | Euro Surveill | 2007 | https://conductscience.org/library/papers/17868596 | PubMed |
| 19 | 21126020 | Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. | J Med Chem | 2011 | https://conductscience.org/library/papers/21126020 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40827962 | Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40827962 | PubMed |
| 34835459 | Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs. | Microorganisms | 2021 | https://conductscience.org/library/papers/34835459 | PubMed |
| 34031040 | Impact of FtsZ Inhibition on the Localization of the Penicillin Binding Proteins in Methicillin-Resistant Staphylococcus aureus. | J Bacteriol | 2021 | https://conductscience.org/library/papers/34031040 | PubMed |
| 31882782 | Structure-Guided Design of a Fluorescent Probe for the Visualization of FtsZ in Clinically Important Gram-Positive and Gram-Negative Bacterial Pathogens. | Sci Rep | 2019 | https://conductscience.org/library/papers/31882782 | PubMed |
| 31045565 | Novel T9 loop conformation of filamenting temperature-sensitive mutant Z from Mycobacterium tuberculosis. | Acta Crystallogr F Struct Biol Commun | 2019 | https://conductscience.org/library/papers/31045565 | PubMed |
| 28555087 | Strategic incorporation of fluorine in the drug discovery of new-generation antitubercular agents targeting bacterial cell division protein FtsZ. | J Fluor Chem | 2017 | https://conductscience.org/library/papers/28555087 | PubMed |
| 27865404 | Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis. | Tuberculosis (Edinb) | 2016 | https://conductscience.org/library/papers/27865404 | PubMed |
| 27301676 | Synthesis and investigation of novel benzimidazole derivatives as antifungal agents. | Bioorg Med Chem | 2016 | https://conductscience.org/library/papers/27301676 | PubMed |
| 27189886 | Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ. | Bioorg Med Chem | 2016 | https://conductscience.org/library/papers/27189886 | PubMed |
| 26756351 | Targeting the Bacterial Division Protein FtsZ. | J Med Chem | 2016 | https://conductscience.org/library/papers/26756351 | PubMed |
| 26245639 | Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. | J Antimicrob Chemother | 2015 | https://conductscience.org/library/papers/26245639 | PubMed |
| 25293977 | Antimicrobial activity of a quinuclidine-based FtsZ inhibitor and its synergistic potential with β-lactam antibiotics. | J Antibiot (Tokyo) | 2015 | https://conductscience.org/library/papers/25293977 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP4F3 | 4051 | PubTator's text mining | https://conductscience.org/library/genes/4051 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24736743
GET https://conductscience.org/api/papers/v1/24736743/authors